NIH-funded research Sbir 2 grant

Investigating a new treatment to prevent lung disease in premature infants

Official title: Phase 1 Safety, Pharmacokinetic study followed by Phase 2a Proof-of-Concept study of AVR-48, a small molecule macrophage modulator to prevent bronchopulmonary dysplasia in neonates

Funded at Ayuvis Research, INC. · NIH-11074691 · Data updated 2026-11-12

This study is testing a new medication called AVR-48 to see if it can help prevent lung problems in premature babies, aiming to improve their breathing and overall health.

More Bronchopulmonary Dysplasia research and trials

Quick facts

Grant typeSbir 2 grant
Study typeNIH-funded research
Funding institutionAyuvis Research, INC.
NIH-funded
Lab location1 site (Fort Worth, United States)
Project startApril 12, 2024
Project endMarch 31, 2027
Funding year2025
Award (this year)$712,481
NIH project number5R44HD112276-02
Project IDNIH-11074691 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are premature infants who are at risk of developing bronchopulmonary dysplasia due to mechanical ventilation.

Less likely to help

Patients who are not premature or who do not require mechanical ventilation may not benefit from this research.

What this research studies

This research focuses on developing a new medication, AVR-48, aimed at preventing bronchopulmonary dysplasia (BPD) in premature infants. The study will first assess the safety and how the drug is processed in the body, followed by a proof-of-concept phase to evaluate its effectiveness. By targeting inflammation and promoting lung development, AVR-48 could significantly improve respiratory function and survival rates in affected neonates. The research utilizes animal models to test the drug's impact on lung health and development.

Why it matters

Potential benefit: If successful, this research could lead to a new treatment that significantly reduces the incidence of bronchopulmonary dysplasia in premature infants, improving their health outcomes.

How similar studies have gone: Previous research has shown promise in using macrophage modulators for similar conditions, indicating potential for success with this novel approach.

Where this research is happening

  • Ayuvis Research, INC.
    Fort Worth, United States
    Active

Researchers

  • Principal investigator: Acharya, Suchismita — Ayuvis Research, INC.
  • Study coordinator: Acharya, Suchismita

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.